Will the Selecta Biosciences Restructuring Pay Off?
Selecta Biosciences shares pushed higher on Friday after the company provided an update on its new streamlined structure under its new president and CEO.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 111
Epizyme Wins FDA Approval and Maybe More for Lymphoma Study
Epizyme shares jumped on Friday after the company announced a set of pipeline updates as well as a key update from the FDA.
How Novavax Is Cashing In for Flu Season
Novavax shares jumped early on Friday after the company reported that its midstage flu vaccine had some positive results.
Air Becomes Unbreathable in Delhi, One of World’s Largest Cities
The air quality in one of the world's largest cities became so bad in the past two days that it is not fit to breathe, even for healthy people.
Teva and Amgen Settle Over Kidney Disease Patent Infringement
Teva Pharmaceutical shares made a handy gain on Thursday after it was announced that the firm has settled with Amgen for its treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on…
Catabasis Gears Up for Late-Stage Duchenne Muscular Dystrophy Trial
Catabasis shares jumped on Thursday after the company provided an update from its late-stage trial for edasalonexent in Duchenne muscular dystrophy.
Big Changes Coming at Atara Biotherapeutics
Atara Biotherapeutics shares dipped on Thursday after the company provided a few business updates.
Are Sesen Bio’s Bladder Cancer Preliminary Results Good Enough?
Sesen Bio shares took a beating on Thursday despite posting positive data for its late-stage trial for patients with high-grade non-muscle invasive bladder cancer.
Why DBV Technologies Is Changing Up Senior Leadership
DBV Technologies shares made a handy gain on Thursday after the company announced that it would be making some changes in its senior leadership ahead of its anticipated resubmission of its Viaskin Peanut Biologics…
Bristol-Myers, Celgene to Tie a $74 Billion Knot
Bristol-Myers has announced a definitive agreement to acquire rival Celgene in a cash and stock deal worth $74 billion. Celgene shareholders are scheduled to receive a 54% premium to Wednesday night's closing stock price.
Merck’s Blockbuster Cancer Drug Keytruda Wins Multiple Approvals in Japan
Merck shares were relatively unchanged early on Thursday after the firm announced that its blockbuster drug Keytruda reported a series of approvals in Japan.
Girl Scouts Release Gluten-Free Cookies
Girl Scout Cookies have been sold since 1917. Among the many flavors and shapes, there has never been a gluten-free product. That changed this year.
Why Value Investors May Flock to Top Biotechs in 2019
Here is a review of the outlook and expectations for 2019 in seven top biotechs valued at $20 billion or more.
How Paratek Could Rise 170% Due to Strong Infectious Disease Treatment Expectations
Could this small clinical-stage emerging pharmaceuticals outfit have upside of almost 200%? That's what one firm has said on the first trading day of 2019.
Why Cara Therapeutics Is One of Wednesday’s Big Winners
Cara Therapeutics shares jumped on Wednesday after the firm announced a key update in its late-stage chronic kidney disease trial.